European prescribers’ attitudes and beliefs on biologicals prescribing and automatic substitution

Category: Original Research
Visits: 93 total, 4 today

Introduction: The European Union (EU) and the European Medicines Agency (EMA) have led the development of a regulatory framework for biosimilars since 2004. By end of December 2019, 64 biosimilars of 15 originator biological medicines have a marketing authorisation in Europe. Now, for the second time, the Alliance for Safe Biologic Medicines (ASBM) asked European prescribers for their views on the prescribing, adverse drug reaction reporting, automatic substitution and switching of biologicals and biosimilars.
Methods: In March 2019, the ASBM surveyed 579 prescribers in France, Germany, Italy, Spain, Switzerland, and the UK. Prescribers were asked for their views on authority over prescribing and dispensing of biologics/biosimilars, reporting biologic/biosimilar use and adverse drug reactions, and switching. There were also questions related to their familiarity with, knowledge of, attitudes to, and beliefs in, biosimilars.
Results: Since the previous European prescriber study conducted in 2013, the percentage of respondents considering themselves highly familiar with biosimilar medicines has increased from 76% to 90%. 4 out of 5 prescribers said they are legally required to report adverse drug reactions that are brought to their attention and they file detailed ADR reports taking 10-20 minutes. 4 out of 5 prescribers feel very strongly about having control over what is prescribed and dispensed to their patients. While highly comfortable prescribing biosimilars to naïve patients, physician comfort level decreased when switching a stable patient to a biosimilar. Comfort level decreased further when prescribers were asked about switching a patient to a biosimilar for non-medical reasons (e.g. cost), and further still if the switch is initiated by a third party.
Conclusion: European physicians have increased their familiarity with biosimilars since the 2013 survey. Physicians increasingly believe they should always have control of treatment decisions including the decision to switch to a biosimilar. It was also highlighted that governments should make multiple therapeutic options available through tenders

Subscribe now to GaBI Journal to view full information of this article to be published in the next journal issue.

Go Back Print

Leave a Reply